Is bortezomib superior to high-dose dexamethasone for the treatment of relapsed multiple myeloma?

Robert Z. Orlowski

doi:10.1038/ncponc0382

Is bortezomib superior to high-dose dexamethasone for the treatment of relapsed multiple myeloma?

Research output: Contribution to journal › Short survey › peer-review

Original language	English (US)
Pages (from-to)	16-17
Number of pages	2
Journal	Nature Clinical Practice Oncology
Volume	3
Issue number	1
DOIs	https://doi.org/10.1038/ncponc0382
State	Published - Jan 2006
Externally published	Yes

Keywords

Bortezomib
Dexamethasone
Multiple myeloma
Proteasome inhibitor

ASJC Scopus subject areas

Oncology

Access to Document

10.1038/ncponc0382

Cite this

@article{63244ca139cc49d4ad9f7134809baf85,

title = "Is bortezomib superior to high-dose dexamethasone for the treatment of relapsed multiple myeloma?",

keywords = "Bortezomib, Dexamethasone, Multiple myeloma, Proteasome inhibitor",

author = "Orlowski, {Robert Z.}",

year = "2006",

month = jan,

doi = "10.1038/ncponc0382",

language = "English (US)",

volume = "3",

pages = "16--17",

journal = "Nature Clinical Practice Oncology",

issn = "1743-4254",